Literature DB >> 1106751

Response of ampicillin resistant Escherichia coli to cephalosporins in an in vitro model simulating conditions of bacterial growth in the urinary bladder.

D Greenwood, F O'Grady.   

Abstract

Five ampicillin resistant strains of Escherichia coli were exposed to cephalosporins in an in vitro model which simulates the hydrokinetic features of the urinary bladder. Although the strains showed substantial zones of inhibition when tested against cephalosporins by the disc diffusion method, the results in the bladder model suggest that, in conditions where the antibiotic concentration is being reduced by dilution and micturition as well as enzymic hydrolysis by the organism, activity of this group of agents may be insufficient to eradicate infection. It is suggested that the results warrant a closer investigation into the efficacy of cephalosporins against ampicillin resistant Gram negative bacilli in vivo.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1106751      PMCID: PMC2072747     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  11 in total

1.  PENICILLINASE-RESISTANT PENICILLINS AND CEPHALOSPORINS.

Authors:  M BARBER; P M WATERWORTH
Journal:  Br Med J       Date:  1964-08-08

2.  The comparative performance of beta-lactam antibiotics against ampicillin sensitive Escherichia coli in conditions simulating those of the infected urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  Br J Exp Pathol       Date:  1974-06

3.  Treatment of "bacterial cystitis" in fully automatic machanical models simulating conditions of bacterial growth in the urinary bladder.

Authors:  F O'Grady; I P Mackintosh; D Greenwood; B W Watson
Journal:  Br J Exp Pathol       Date:  1973-06

4.  Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies.

Authors:  D Greenwood; F O'Grady
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

5.  Antibacterial action of "broad-spectrum" penicillins, cephalosporins and other antibiotics against Gram-negative bacilli isolated from bacteremic patients.

Authors:  N H Steigbigel; C E McCall; C W Reed; M Finland
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

6.  Predictive value of "endogenous washout" test and uroradiology in assessing likely response of urinary-tract infection to treatment.

Authors:  W R Cattell; C A Charlton; I K Fry; A McSherry; F O'GRADY
Journal:  Lancet       Date:  1972-07-29       Impact factor: 79.321

7.  Relation between residual urine volume and response to treatment of urinary infection.

Authors:  D G Shand; C C Nimmon; F O'Grady; W R Cattell
Journal:  Lancet       Date:  1970-06-20       Impact factor: 79.321

8.  Development and further applications of a simple turbidity cell for continuously monitoring bacterial growth.

Authors:  I P Mackintosh; B W Watson; F O'Grady
Journal:  Phys Med Biol       Date:  1973-03       Impact factor: 3.609

9.  Use and control of cephalosporins.

Authors:  S Eykyn
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

10.  Estimation of residual urine volume with 131 I-hippuran.

Authors:  D G Shand; J C MacKenzie; W R Cattell; J Cato
Journal:  Br J Urol       Date:  1968-04
View more
  4 in total

1.  Letter: Co-trimoxazole and cephalexin in urinary tract infection.

Authors:  D Greenwood; F O'Grady
Journal:  Br Med J       Date:  1976-05-01

2.  Factors influencing the response of Escherichia coli to antibiotics in conditions prevailing in the infected urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  Br J Exp Pathol       Date:  1976-06

3.  Dual-action cephalosporin utilizing a novel therapeutic principle.

Authors:  D Greenwood; F O'Grady
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

4.  Combined action of decreasing concentrations of azlocillin and sisomicin on Pseudomonas aeruginosa as assessed in a dynamic in vitro model.

Authors:  I Haller
Journal:  Infection       Date:  1982       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.